Roundtable
Advertisement
The panelists discuss promising new advancements and novel therapies for treating RCC, including LAG-3 and CAR-T therapies.
The panel discusses how designing effective trials could refine the approach to treatment strategies for RCC.
Part 3 of this roundtable examines adjuvant pembrolizumab and the role of TKIs in treatment sequencing for RCC.
The panelists examine the data on TKIs and immunotherapy for RCC from the TiNivo-2 trial.
Part 1 of this roundtable examines the key differences between the CONTACT-03 and TiNivo-2 trials.
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
In part four of this roundtable series, the panelists discuss CRPC and the typical patterns of presentation.
Part three of this roundtable delves into genomic biomarkers and the use of doublet and triplet therapies for mHSPC.
Part two of the roundtable series explores ADT and novel hormonal therapies for patients with prostate cancer.
Part one of a roundtable series on prostate cancer, focusing on defining mHSPC and mCRPC.
The final segment of this roundtable series discusses radiopharmaceuticals and PARP inhibitors.
Part five of this roundtable series covers data and insights from the ARANOTE and PEACE 3 trials.
Part four of a PCa roundtable series focuses on the effectiveness of ADT with triplet therapy.
Part three of this prostate cancer roundtable covers prognostic factors such as Gleason scores and genomic assays.
Part two of this roundtable features a discussion on the role of bone scans compared to the newer PSMA PET scans.
The first part of this roundtable focuses on the impact of recent research on clinical practice.
The final segment of this roundtable series addresses the future of immunotherapy combinations.
The fifth segment of this roundtable series focuses on the use of circulating tumor DNA (ctDNA) in managing bladder cancer.
In part four of this roundtable, the use of immunotherapy in the adjuvant setting for bladder cancer is discussed.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.